PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1211733
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1211733
Multiple unit pellet systems market size was valued at USD 3,199.5 Million in 2022, expanding at a CAGR of 4.2% from 2023 to 2030.
Multiple unit pellet systems (MUPS) are used to help people swallow capsules more easily and in comparison to suspensions it improves their physicochemical stability. MUPS includes pellets, granules, microcapsules, microspheres, and minitablets. Additionally, MUPS are very convenient dosage forms and have great bioavailability. Moreover, due to their user-friendly option to regular tablets, the MUPS market is projected to grow during the forecast period.
Market Dynamics
MUPS offers various advantages as compared to simple tablets and capsules such as the reduction in intestinal mucosa irritation with simple units' and better dose adjustment. In addition, based on advantages and due to high patient compliance MUPS market is anticipated to grow across the globe. However, the challenging and complex production process for MUPS tablets is one of the key factors that can hamper the MUPS market growth.
Moreover, increasing demand for modified-release MUPS products and rising demand for gastro-retentive drug delivery systems are such factors that will further stimulate the MUPS market growth. Furthermore, the rising use of pellets in drug formulations is expected to provide good opportunities in the MUPS market. Additionally, based on their benefits including the flexibility they provide as compared to conventional forms, their ability to offer modified release, great therapeutic, taste-masked formulation, and immediate release. Owing to such benefits MUPS formulation is expected to gain adoption over traditional drug delivery systems.
Segmentation Analysis:
The Worldwide Multiple Unit Pellet Systems Market is segmented on the basis of formulation, dosage form, drug class, distribution channel, and region.
The market is divided into three categories based on formulation: delayed-release dosage form, extended-release dosage form, delayed-release orodispersible dosage form, and others. The delayed-release dosage form segment is expected to hold the market share. It offers drugs at a pre-determined rate, supporting the therapeutic effect, in comparison to the traditional delivery systems.
The market is divided into three categories based on dosage form: tablets, capsules, sachets, and others. The tablets segment is estimated to possess during the forecast period. MUPS tablets are a convenient and easy alternative to regular tablets that are gaining traction for the tablets segment globally.
The market is divided into four categories based on drug class: anti-hypertensive, proton pump inhibitors, antibiotics, analgesics, and others. The proton pump inhibitors segment is expected to be the most preferable drug class. Proton pump inhibitor is available and largely accepted across the globe.
The market is divided into five categories based on distribution channels: hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. Hospital pharmacies are expected to dominate the market share globally. In hospitals, the number of patients is increasing rapidly which further aided hospital pharmacies segment growth.
Competitive Landscape:
The rising number of FDA approvals for pharmaceuticals is one of the key factors propelling the MIPS market growth. To extend their product portfolio and to make a strong position in the industry, companies are focusing on getting fast-track drug approvals. Additionally, such market players are implementing a variety of key categories to strengthen their market share including mergers & acquisitions, new launches, collaborations, R&D spending, distribution network development, and partnerships. Through a variety of platforms, companies sell their products such as e-commerce websites, retailers, distributors, corporate websites, and end consumers.
For instance, in May 2023, PERRIGO announced U.S. FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES, 20 mg over-the-counter (OTC). This capsule is used for the treatment of frequent heartburn. The product will be sold under the retailer's store brand name comparable to Prilosec OTC®.
Key features of the study:
This proposed research study on multiple unit pellet systems market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year.
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for multiple unit pellet systems market.
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the multiple unit pellet systems market.
Impact of COVID-19 on Multiple Unit Pellet Systems Market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on multiple unit pellet systems market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the multiple unit pellet systems market, we have also included competitive landscape and key innovator analysis for the Air-to-Air Heat Pumps market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the multiple unit pellet systems market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
The global multiple unit pellet systems market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MULTIPLE UNIT PELLET SYSTEMS MARKET KEY PLAYERS
GlaxoSmithKline Plc
Eli Lilly and Company
Mylan Pharmaceuticals Inc.
GlaxoSmithKline Plc
Bayer AG
Cipla Ltd.
Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
Merck KGaA
Perrigo Company Plc.
AbbVie (Allergan)
AstraZeneca plc
Astellas Pharma Inc.
Endo International Inc.
Teva Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Ltd.
Novartis AG
Galderma SA
Takeda Pharmaceutical Company Ltd.
GLOBAL MULTIPLE UNIT PELLET SYSTEMS MARKET, BY FORMULATION
Extended Release Dosage Form
Delayed Release Dosage Form
Delayed Release Orodispersible Dosage Form
Other
GLOBAL MULTIPLE UNIT PELLET SYSTEMS MARKET, BY DOSAGE FORM
Tablets
Capsules
Sachets
Others
GLOBAL MULTIPLE UNIT PELLET SYSTEMS MARKET, BY DRUG CLASS
Anti-Hypertensive
Proton Pump Inhibitors
Antibiotics
Analgesics
Others
GLOBAL MULTIPLE UNIT PELLET SYSTEMS MARKET, BY DISTRIBUTION CHANNEL
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
GLOBAL MULTIPLE UNIT PELLET SYSTEMS MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA